Cargando…
Immunosuppressive Signaling Pathways as Targeted Cancer Therapies
Immune response has been shown to play an important role in defining patient prognosis and response to cancer treatment. Tumor-induced immunosuppression encouraged the recent development of new chemotherapeutic agents that assists in the augmentation of immune responses. Molecular mechanisms that tu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945019/ https://www.ncbi.nlm.nih.gov/pubmed/35327484 http://dx.doi.org/10.3390/biomedicines10030682 |
_version_ | 1784673852097298432 |
---|---|
author | Setlai, Botle Precious Hull, Rodney Bida, Meshack Durandt, Chrisna Mulaudzi, Thanyani Victor Chatziioannou, Aristotelis Dlamini, Zodwa |
author_facet | Setlai, Botle Precious Hull, Rodney Bida, Meshack Durandt, Chrisna Mulaudzi, Thanyani Victor Chatziioannou, Aristotelis Dlamini, Zodwa |
author_sort | Setlai, Botle Precious |
collection | PubMed |
description | Immune response has been shown to play an important role in defining patient prognosis and response to cancer treatment. Tumor-induced immunosuppression encouraged the recent development of new chemotherapeutic agents that assists in the augmentation of immune responses. Molecular mechanisms that tumors use to evade immunosurveillance are attributed to their ability to alter antigen processing/presentation pathways and the tumor microenvironment. Cancer cells take advantage of normal molecular and immunoregulatory machinery to survive and thrive. Cancer cells constantly adjust their genetic makeup using several mechanisms such as nucleotide excision repair as well as microsatellite and chromosomal instability, thus giving rise to new variants with reduced immunogenicity and the ability to continue to grow without restrictions. This review will focus on the central molecular signaling pathways involved in immunosuppressive cells and briefly discuss how cancer cells evade immunosurveillance by manipulating antigen processing cells and related proteins. Secondly, the review will discuss how these pathways can be utilized for the implementation of precision medicine and deciphering drug resistance. |
format | Online Article Text |
id | pubmed-8945019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89450192022-03-25 Immunosuppressive Signaling Pathways as Targeted Cancer Therapies Setlai, Botle Precious Hull, Rodney Bida, Meshack Durandt, Chrisna Mulaudzi, Thanyani Victor Chatziioannou, Aristotelis Dlamini, Zodwa Biomedicines Review Immune response has been shown to play an important role in defining patient prognosis and response to cancer treatment. Tumor-induced immunosuppression encouraged the recent development of new chemotherapeutic agents that assists in the augmentation of immune responses. Molecular mechanisms that tumors use to evade immunosurveillance are attributed to their ability to alter antigen processing/presentation pathways and the tumor microenvironment. Cancer cells take advantage of normal molecular and immunoregulatory machinery to survive and thrive. Cancer cells constantly adjust their genetic makeup using several mechanisms such as nucleotide excision repair as well as microsatellite and chromosomal instability, thus giving rise to new variants with reduced immunogenicity and the ability to continue to grow without restrictions. This review will focus on the central molecular signaling pathways involved in immunosuppressive cells and briefly discuss how cancer cells evade immunosurveillance by manipulating antigen processing cells and related proteins. Secondly, the review will discuss how these pathways can be utilized for the implementation of precision medicine and deciphering drug resistance. MDPI 2022-03-16 /pmc/articles/PMC8945019/ /pubmed/35327484 http://dx.doi.org/10.3390/biomedicines10030682 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Setlai, Botle Precious Hull, Rodney Bida, Meshack Durandt, Chrisna Mulaudzi, Thanyani Victor Chatziioannou, Aristotelis Dlamini, Zodwa Immunosuppressive Signaling Pathways as Targeted Cancer Therapies |
title | Immunosuppressive Signaling Pathways as Targeted Cancer Therapies |
title_full | Immunosuppressive Signaling Pathways as Targeted Cancer Therapies |
title_fullStr | Immunosuppressive Signaling Pathways as Targeted Cancer Therapies |
title_full_unstemmed | Immunosuppressive Signaling Pathways as Targeted Cancer Therapies |
title_short | Immunosuppressive Signaling Pathways as Targeted Cancer Therapies |
title_sort | immunosuppressive signaling pathways as targeted cancer therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945019/ https://www.ncbi.nlm.nih.gov/pubmed/35327484 http://dx.doi.org/10.3390/biomedicines10030682 |
work_keys_str_mv | AT setlaibotleprecious immunosuppressivesignalingpathwaysastargetedcancertherapies AT hullrodney immunosuppressivesignalingpathwaysastargetedcancertherapies AT bidameshack immunosuppressivesignalingpathwaysastargetedcancertherapies AT durandtchrisna immunosuppressivesignalingpathwaysastargetedcancertherapies AT mulaudzithanyanivictor immunosuppressivesignalingpathwaysastargetedcancertherapies AT chatziioannouaristotelis immunosuppressivesignalingpathwaysastargetedcancertherapies AT dlaminizodwa immunosuppressivesignalingpathwaysastargetedcancertherapies |